4D-150 for Diabetic Macular Edema

(4SIGHT Trial)

This trial tests a new treatment for diabetic macular edema (DME), a condition that causes fluid buildup in the eye and leads to vision problems. The trial compares a single injection of the experimental treatment 4D-150 with the existing treatment, EYLEA (aflibercept). It aims to assess the safety and effectiveness of the new treatment, as well as the duration of its effects. Suitable participants have diabetes and vision issues due to DME and have previously responded well to EYLEA. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial team for guidance.

Research has shown that 4D-150, a gene therapy being tested for diabetic macular edema, is safe. In earlier studies, patients who received 4D-150 experienced no swelling inside the eye, indicating it is well-tolerated. This treatment involves a one-time injection, potentially reducing the need for repeat procedures.

Conversely, Aflibercept, known as EYLEA, has already received FDA approval for treating diabetic macular edema. Studies confirm its safety, as it has been widely used and is considered an effective treatment option.

Unlike the standard of care for diabetic macular edema, which often includes treatments like EYLEA (aflibercept) injections, 4D-150 is unique because it uses gene therapy delivered directly into the eye. This innovative approach aims to provide longer-lasting effects by introducing genetic material that helps the body produce therapeutic proteins on its own. Researchers are particularly excited because this could mean fewer injections for patients and potentially more durable control of the condition, improving both convenience and outcomes.

Research has shown that 4D-150, a gene therapy injected into the eye, may help treat diabetic macular edema (DME). In one study, patients who received 4D-150 improved their vision by an average of 10.8 letters on an eye chart over two years. This treatment aims to maintain better vision while reducing the need for frequent eye injections. Trials have also demonstrated its safety, with no major inflammation reported. In this trial, researchers are comparing 4D-150 to aflibercept, a well-known DME treatment that improves vision and reduces eye swelling. Both treatments are being studied in separate arms to evaluate their effectiveness in managing DME.³⁴⁶⁷⁸